Cassava Sciences, Inc.

Clinical trials sponsored by Cassava Sciences, Inc., explained in plain language.

Cassava Sciences, Inc. SAVA NASDAQ

Biotech developing treatments for Alzheimer's disease.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Terminated 1

Alzheimer's drug simufilam trial halted Mid-Study

Disease control Stopped early

This study tested a drug called simufilam in over 1,000 people with mild-to-moderate Alzheimer's disease. Participants took either 50 mg, 100 mg, or a placebo twice daily for 76 weeks. The goal was to see if simufilam could slow memory loss and help with daily activities. However…

Phase 3 • Sponsor: Cassava Sciences, Inc. • Aim: Disease control

Last updated Jun 27, 2026 07:51 UTC

Cassava Sciences, Inc.

Alzheimer's drug simufilam trial halted Mid-Study